Ionis Pharmaceuticals Inc (IONS): Stanley T Crooke , Chairman and CEO of Ionis Pharmaceuticals Inc sold 22,000 shares on Sep 21, 2016. The Insider selling transaction was reported by the company on Sep 23, 2016 to the Securities and Exchange Commission. The shares were sold at $35.50 per share for a total value of $781,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 6, 2016, B Lynne Parshall (COO) sold 12,500 shares at $29.93 per share price.On Jun 2, 2016, Frederick T Muto (director) sold 12,500 shares at $22.31 per share price.Also, On Apr 7, 2016, Patrick R. O’neil (SVP, Legal & General Counsel) sold 1,000 shares at $45.00 per share price.On Apr 7, 2016, Stanley T Crooke (Chairman and CEO) sold 11,000 shares at $46.12 per share price.
Company has been under the radar of several Street Analysts.Ionis Pharmaceuticals Inc is Reiterated by Piper Jaffray to Overweight and the brokerage firm has raised the Price Target to $ 46 from a previous price target of $36 .The Rating was issued on Aug 10, 2016.Ionis Pharmaceuticals Inc is Initiated by Morgan Stanley to Equal-Weight and the brokerage firm has set the Price Target at $37. The Rating was issued on Aug 3, 2016.Ionis Pharmaceuticals Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 64 from a previous price target of $55 .The Rating was issued on Aug 2, 2016.Ionis Pharmaceuticals Inc is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 41 from a previous price target of $26 .The Rating was issued on Aug 2, 2016.
Ionis Pharmaceuticals Inc. formerly Isis Pharmaceuticals Inc. is a ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused on discovering and developing antisense drugs. Its antisense drugs are used to treat a range of diseases including cardiovascular; metabolic; severe and rare diseases including neurological disorders and cancer. Volanesorsen is a drug indicated to treat patients with high triglyceride levels including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. It is focused on bringing its late-stage Phase III drugs nusinersen volanesorsen and IONIS-TTR to the market. Its lipid-lowering product KYNAMRO (mipomersen sodium) injection is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH). Its products also include Alicaforsen IONIS-DMPK-2.5 Plazomicin and IONIS-GCGR.